|
|
 |
|
Viewing report
|
|
|
|
The Specialty Pharma Market Outlook: Key Players, New Company Growth Models and Emerging Opportunities
Business Insights, Oct 2006, Pages: 199
While the specialty pharma sector has traditionally capitalized on opportunities from Big Pharma, competitive pressure and the maturing market is forcing them to develop new specialization strategies. These pressures, such as commoditization of drug delivery technologies and competition from foreign bulk generics manufacturers, are driving new company growth models and a focus on targeted portfolios, stronger late-stage drug development capabilities, M&A and in-licensing activity. ‘The Specialty Pharma Market Outlook ’evaluates current specialty pharma models, financial performance, core strategies and the future outlook of specialty pharma companies. This report also examines key specialty markets, providing valuable insights into market dynamics while profiling trends influencing market opportunities in therapeutic indications. Discover how leaders in the specialty pharma market are achieving high growth, benchmark your strategies against those of the industry ’s leaders and identify profitable partnering opportunities with the help of this new report.
Key Findings of this Report:
- In 2005, the specialty pharmaceutical market was valued at $52m.
- Allergan’s accrued the highest revenues in 2005 reported at $2.3bn and is forecast to maintain a strong presence in niche marketing. The company currently draws some 57.0% of its revenues from its ophthalmology segment.
- Despite high genericization, treatments for cardiovascular disorders continue to remain popular among specialty pharmaceutical companies. This indication generated revenues of $4,600m in 2005 with anti-hypertensives accounting for $1.2bn or 26.7% of total sales.
- In 2005 CNS disorders held the highest share of the specialty pharmaceutical market of any therapeutic area, estimated at 22.1% or $11,500m.
- Increased competition for the strongest licensing opportunities is forecast to affect companies specializing in sales and marketing, with scale remaining a key constituent of competitive advantage.
Key Questions Answered in this Report:
- What are the critical factors that define technological specialization strategies among specialty pharma companies?
- Why are companies with drug delivery/reformulation as their specialization forecast to face challenges in the future?
- What are the current market trends within the major specialty therapy areas of cardiovascular, CNS disorders, ophthalmology, urology, dermatology and women’s health?
- What sub-indications are driving current growth in these major therapeutic areas?
- Which types of companies are best positioned to succeed in the specialty pharmaceutical markets and why?
- What are the key emerging strategies for pharmaceutical companies to establish a presence and operate within the specialty pharmaceutical market in the future?
Top 5 Reasons to Order your Copy Today:
- Gain a detailed overview of the speciality pharmaceutical market, including segmentation by company type and analysis of deal flow, licensing and M&A activity.
- Identify future therapeutic opportunities and threats in the major therapy areas of cardiovascular, CNS, ophthalmology, dermatology, women’s health and urology.
- Analyze growth strategies of the leading players, using the product portfolio, SWOT and financial performance analysis contained in this report.
- Understand the current market dynamics of pharma companies focusing on niche indications.
- Implement the most attractive growth models and company strategies for future success.
|
|
|
|
